Valneva SE (VALN) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
Valneva SE (VALN) Net Income towards Common Stockholders Growth (1y) (2022 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
Valneva SE |
167.33 Mn |
44.10 Mn |
5.08 Mn |
-342.51% |
| Date | Value |
|---|
| Mar 31, 2026 |
-342.51% |
| Dec 31, 2025 |
-161.21% |
| Sep 30, 2025 |
-217.37% |
| Jun 30, 2025 |
46.97% |
| Mar 31, 2025 |
-108.46% |
| Dec 31, 2024 |
16.72% |
| Sep 30, 2024 |
43.46% |
| Jun 30, 2024 |
-15.85% |
| Mar 31, 2024 |
516.53% |
| Dec 31, 2023 |
53.39% |
| Sep 30, 2023 |
-133.22% |
| Jun 30, 2023 |
86.77% |
| Mar 31, 2023 |
36.69% |
| Dec 31, 2022 |
-129.70% |
| Sep 30, 2022 |
139.18% |
| Jun 30, 2022 |
-122.07% |
| Mar 31, 2022 |
18.08% |
